We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Visa, Walmart, Abbott Laboratories, UnitedHealth Group and Oracle
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 13, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa Inc. (V), Walmart Inc. (WMT - Free Report) , Abbott Laboratories (ABT - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Oracle Corporation (ORCL - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Visa, Walmart and Abbott
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa, Walmart and Abbott Laboratories. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Visa shares have modestly outperformed the Zacks Financial Transaction Services industry in the year-to-date period (+10% vs. +7.5%), but has lagged Mastercard given Visa's greater exposure to cross-border transactions that have suffered due to pandemic-related travel restrictions. These issues notwithstanding, the Zacks analyst believes that numerous acquisitions and alliances have paved the way for long-term growth .
Consistent investments in newer technologies have enabled Visa to further strengthen its leading position in the payments market. Also, the shift to new payment methods such as mobile, cards, online and via wearables bodes well for the long haul. The acquisition of Visa Europe is a growth strategy as well. Its strong balance sheet enables it to make acquisitions and fund capital expenditure.
Its strong cash position enables effective capital deployment measures for its shareholders. However, high operating expenses put operating margins under pressure. Ramped-up client initiatives will dent the top line. It is likely to see a slowdown in cross-border business due to the coronavirus outbreak.
Walmart shares have performed in-line with the Zacks Supermarkets industry’s +20.2% gain in the year-to-date period on the back of rising demand for grocery and general merchandise items amid coronavirus-led stay-at-home trends. Walmart's long-term outlook has also improved significantly given the company's material digital investments as a result of which online sales have been growing strongly.
Stay-at-home trends are also boosting e-commerce sales, which soared 97% in second-quarter fiscal 2021. During the quarter, sales and earnings beat the consensus mark and grew year over year, with U.S. comps rising for the 24th straight time. In the U.S. segment, store and online sales remained strong, supported by government stimulus and the company's concerted delivery efforts.
To this end, the recently unveiled Walmart+ plan is likely to be fruitful. Further, Walmart is set to gain from its measures like additional hiring to address customers’ core shopping patterns this holiday season. Such upsides are likely to help the company battle high COVID-19- costs.
Abbott shares have gained +27.7% over the past six months against the Zacks Medical Products industry’s rise of +14.6%. The Zacks analyst believes that Abbott's second-quarter 2020 figures declined year over year due to the pandemic-led fall in procedure volumes in many businesses.
However, the company’s Diabetes Care, Nutrition, and EPD arms collectively grew more than 9% in the first half of 2020 leveraging on the pandemic situation. Apart from the latest EUA for COVID-19 rapid antigen test, the company also obtained FDA for Libre 2 as an iCGM. It also received CE Mark for TriClip.
However, Abbott’s Core Laboratory Diagnostics, cardiovascular and neuromodulation sales were significantly down in the reported quarter affected by lower demand in the past few months.
Other noteworthy reports we are featuring today include UnitedHealth Group and Oracle.
Zacks’ 2020 Election Stock Report:
In addition to the companies you learned about above, we invite you to learn more about profiting from the upcoming presidential election. Trillions of dollars will shift into new market sectors after the votes are tallied, and investors could see significant gains. This report reveals specific stocks that could soar: 6 if Trump wins, 6 if Biden wins.Check out the 2020 Election Stock Report >>
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Visa, Walmart, Abbott Laboratories, UnitedHealth Group and Oracle
For Immediate Release
Chicago, IL – October 13, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa Inc. (V), Walmart Inc. (WMT - Free Report) , Abbott Laboratories (ABT - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Oracle Corporation (ORCL - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Visa, Walmart and Abbott
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa, Walmart and Abbott Laboratories. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Visa shares have modestly outperformed the Zacks Financial Transaction Services industry in the year-to-date period (+10% vs. +7.5%), but has lagged Mastercard given Visa's greater exposure to cross-border transactions that have suffered due to pandemic-related travel restrictions. These issues notwithstanding, the Zacks analyst believes that numerous acquisitions and alliances have paved the way for long-term growth .
Consistent investments in newer technologies have enabled Visa to further strengthen its leading position in the payments market. Also, the shift to new payment methods such as mobile, cards, online and via wearables bodes well for the long haul. The acquisition of Visa Europe is a growth strategy as well. Its strong balance sheet enables it to make acquisitions and fund capital expenditure.
Its strong cash position enables effective capital deployment measures for its shareholders. However, high operating expenses put operating margins under pressure. Ramped-up client initiatives will dent the top line. It is likely to see a slowdown in cross-border business due to the coronavirus outbreak.
(You can read the full research report on Visa here >>>)
Walmart shares have performed in-line with the Zacks Supermarkets industry’s +20.2% gain in the year-to-date period on the back of rising demand for grocery and general merchandise items amid coronavirus-led stay-at-home trends. Walmart's long-term outlook has also improved significantly given the company's material digital investments as a result of which online sales have been growing strongly.
Stay-at-home trends are also boosting e-commerce sales, which soared 97% in second-quarter fiscal 2021. During the quarter, sales and earnings beat the consensus mark and grew year over year, with U.S. comps rising for the 24th straight time. In the U.S. segment, store and online sales remained strong, supported by government stimulus and the company's concerted delivery efforts.
To this end, the recently unveiled Walmart+ plan is likely to be fruitful. Further, Walmart is set to gain from its measures like additional hiring to address customers’ core shopping patterns this holiday season. Such upsides are likely to help the company battle high COVID-19- costs.
(You can read the full research report on Walmart here >>>)
Abbott shares have gained +27.7% over the past six months against the Zacks Medical Products industry’s rise of +14.6%. The Zacks analyst believes that Abbott's second-quarter 2020 figures declined year over year due to the pandemic-led fall in procedure volumes in many businesses.
However, the company’s Diabetes Care, Nutrition, and EPD arms collectively grew more than 9% in the first half of 2020 leveraging on the pandemic situation. Apart from the latest EUA for COVID-19 rapid antigen test, the company also obtained FDA for Libre 2 as an iCGM. It also received CE Mark for TriClip.
However, Abbott’s Core Laboratory Diagnostics, cardiovascular and neuromodulation sales were significantly down in the reported quarter affected by lower demand in the past few months.
(You can read the full research report on Abbott here >>>)
Other noteworthy reports we are featuring today include UnitedHealth Group and Oracle.
Zacks’ 2020 Election Stock Report:
In addition to the companies you learned about above, we invite you to learn more about profiting from the upcoming presidential election. Trillions of dollars will shift into new market sectors after the votes are tallied, and investors could see significant gains. This report reveals specific stocks that could soar: 6 if Trump wins, 6 if Biden wins.Check out the 2020 Election Stock Report >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.